The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours

Trial Profile

The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms LUMEN
  • Most Recent Events

    • 01 Sep 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 01 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 04 Apr 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top